FDA approves Regeneron’s hearing loss gene therapy
BioPharma Dive
Otarmeni, now cleared to treat a rare, inherited kind of hearing loss, is the first gene therapy cleared under the FDA s national priority voucher program and will be offered to eligible patients at n
pharminent
April 23, 2026 (Last updated: April 24, 2026)
BioPharma Dive
Otarmeni, now cleared to treat a rare, inherited kind of hearing loss, is the first gene therapy cleared under the FDA s national priority voucher program and will be offered to eligible patients at n